妊娠期高血压疾病治疗中低分子肝素的应用效果

Effect of Low Molecular Weight Heparin in the Treatment of Hypertensive Diseases during Pregnancy

目的探究妊娠期高血压疾病治疗中低分子肝素的应用效果。方法便利选取2021年4月—2022年5月淄博市妇幼保健院收治的62例妊娠期高血压患者作为研究对象,随机分为LSM组(31例)与DFZ组(31例),LSM组采用硫酸镁治疗,DFZ组采用低分子肝素治疗。比较两组患者的治疗效果、血压水平、临床指标(脐血流RI值、脐血流S/D值、血黏度、血细胞压积、心率、出血量、凝血酶原时间、D-二聚体)、不良反应发生率、不良妊娠结局发生率。结果治疗前,两组患者血压水平及各项临床指标比较,差异无统计学意义(P>0.05);治疗后,DFZ组治疗效果、血压水平、临床指标均优于LSM组,不良反应发生率低于LSM组,差异有统计学意义(P<0.05)。DFZ组不良妊娠结局发生率6.45%(2/31)低于LSM组的29.03%(9/31),差异有统计学意义(χ^(2)=5.415,P=0.020)。结论在妊娠期高血压疾病治疗中实施低分子肝素干预可提高患者治疗效果,改善各项临床指标,减少不良反应发生率及不良妊娠结局发生率。

Objective To explore the effect of low molecular weight heparin in the treatment of hypertensive diseases during pregnancy.Methods 62 patients with pregnancy induced hypertension admitted to Zibo Maternal and Child Health Care Hospital from April 2021 to May 2022 were conveniently selected as research objects,and randomly divided into LSM group(31 cases)and DFZ group(31 cases).LSM group was treated with magnesium sulfate,and DFZ group was treated with low molecular weight heparin.The treatment effect,blood pressure level,clinical indicators(RI value of umbilical blood flow,S/D value of umbilical blood flow,blood viscosity,hematocrit,heart rate,bleeding volume,prothrombin time,D-dimer),incidence of adverse reactions and incidence of adverse pregnancy outcomes were compared between the two groups.Results Before treatment,there was no statistically significant difference in blood pressure levels and various clinical indicators between the two groups of patients(P>0.05);after treatment,the treatment effect,blood pressure level,and clinical indicators of the DFZ group were better than those of the LSM group,and the incidence of adverse reactions was lower than that of the LSM group,and the difference was statistically significant(P<0.05).The incidence of adverse pregnancy outcomes in the DFZ group was 6.45%(2/31)lower than 29.03%(9/31)in the LSM group,and the difference was statistically significant(χ^(2)=5.415,P=0.020).Conclusion The implementation of low molecular weight heparin intervention in the treatment of hypertensive diseases in pregnancy can improve the therapeutic effect of patients,improve the clinical indicators of patients,and reduce the incidence of adverse reactions and adverse pregnancy outcomes.